RxDoctor Payments Data

Mohammed Ahmed, PA

Physician Assistant · Edinburg, TXNPI 1235153396

Payments from drug & device makers

$2,297in general payments, 2019–2025

Across 131 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$513
  • Novo Nordisk$403
  • Lilly USA, LLC$247
  • AbbVie$215
  • AstraZeneca$129
  • Astellas Pharma US Inc$128
  • plus $661 from 17 others

What the payments were for

  • Food & beverage$2,28399%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,297 in reported general payments places this provider in the 75th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$51,555
Medicare patients
65
Services billed
1,040

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide161$227,080
FarxigaDapagliflozin Propanediol104$96,374
MounjaroTirzepatide64$90,977
Tresiba Flextouch U-200Insulin Degludec107$90,369
TrulicityDulaglutide48$71,634
RybelsusSemaglutide36$59,407
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$39,444
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog37$27,714
JanuviaSitagliptin Phosphate16$23,427
JardianceEmpagliflozin19$14,832
EliquisApixaban20$14,656
LinzessLinaclotide12$13,402
Novolog FlexpenInsulin Aspart46$10,719
Humalog Kwikpen U-200Insulin Lispro12$10,436
Soliqua 100-33Insulin Glargine/Lixisenatide13$10,429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$403$286,487197 claims
Lilly USA, LLCMounjaro, Trulicity$247$162,611112 claims
AstraZenecaFarxiga, Brilinta$129$104,518115 claims
GSKTrelegy Ellipta$513$39,44455 claims
Boehringer IngelheimJardiance$108$14,83219 claims
AbbVieLinzess$215$13,40212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Edinburg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →